Abstract

Aims: To investigate the correlation between thioredoxin-interacting protein (TXNIP) and peripheral nerve conduction velocity (NCV) in patients with type 2 diabetes mellitus.Methods: In total, 338 patients with type 2 diabetes mellitus (T2DM) were included in this study. We collected the clinical data and measured the motor conduction velocities of the bilateral ulnar nerve, median nerve, tibial nerve, and common peroneal nerve, and the sensory conduction velocities of the ulnar nerve, median nerve, sural nerve, and superficial peroneal nerve. According to the results, the patients were divided into two groups: normal peripheral nerve conduction group (NCVN group) and abnormal peripheral nerve conduction group (NCVA group). The two groups were then compared in terms of the conventional biochemical index and the sugar metabolic index as well as the serum levels of TXNIP, reduced glutathione (GSH), total superoxide dismutase (SOD), malondialdehyde (MDA), and tumor necrosis factor alpha (TNF-α). The correlation between TXNIP and NCV was also analyzed.Results: Compared with the NCVN group, the TXNIP and MDA values were significantly increased in the NCVA group (P < 0.05). Among the patients with T2DM, age, fasting glucose, SDBG, and TXNIP were risk factors for NCV abnormality, while vitamin D3 was a protective factor. After adjusting for related confounding factors, TXNIP was significantly correlated with NCV (P < 0.05). Among the patients with T2DM, TXNIP was an independent risk factor for left ulnar motor conduction velocity (MCV), right ulnar MCV, left median MCV, and right median MCV. TNF-α was identified as a positive influencing factor for serum TXNIP, while serum TXNIP was a positive factor for TNF-α and MDA (both P < 0.05).Conclusion: Serum TXNIP is related to NCV in T2DM patients. In combination with oxidative stress and inflammation, TXNIP may affect diabetic peripheral neuropathy (DPN).

Highlights

  • Diabetic peripheral neuropathy (DPN) is a common complication of diabetes mellitus (DM), and occurs in 30–60% of diabetic patients (1)

  • Serum thioredoxin-interacting protein (TXNIP) is related to nerve conduction velocity (NCV) in type 2 diabetes mellitus (T2DM) patients

  • Laboratory Data Collection Fasting venous blood was collected from patients who fasted for more than 8 h prior to testing for serum albumin (Alb), alanine aminotransferase (ALT), aspartate aminotransferase (AST), triglycerides (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), creatinine (Cr), blood urea nitrogen (BUN), glomerular filtration rate (GFR), uric acid (UA), fasting blood glucose (FBG); these indicators were analyzed by professionals using a fully automatic biochemical analyzer

Read more

Summary

Introduction

Diabetic peripheral neuropathy (DPN) is a common complication of diabetes mellitus (DM), and occurs in 30–60% of diabetic patients (1). The pathogenesis of DPN includes metabolic abnormality, insulin resistance, growth factor deficiency, oxidative stress, and inflammatory factor activation. Among these factors, oxidative stress plays an important role in peripheral neuropathy. TXNIP was first identified in HL-60 promyelocytic leukemia cells treated with 1,25-dihydroxyvitamin D3 (3). It is a 46-kD protein composed of 391 amino acid residues that is encoded on human chromosome 1q21.1 and is expressed in many tissues (4). Studies have shown that TXNIP can affect the development of diabetic nephropathy by inhibiting endogenous oxidative stress (6). We investigated the relationship between serum TXNIP levels and NCV in patients with type 2 diabetes to provide a new target for the prevention and treatment of DPN

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call